Latest Euronext Paris News


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

11/25/2017 05:50 AM


Capital.com

ACCOR NV (ACNV) Is Yet to See Trading Action on Nov 24
UtahHerald.com
Euronext Paris, which was formerly known as Paris Bourse, is the main stock exchange in France. It is part of Euronext, a pan-European stock exchange across five European cities including Paris, London, Lisbon, Brussels, and Amsterdam. Euronext was ...
Societe Francs d Gstn et dInv SOFRAGI SA (SOFR) Increased 0% on Nov 24Wolcott Daily
PARIS-ORLEANS NV (PAONV) Is Yet to See Trading Action on Nov 23Key Gazette
ABC Arbitrage SA (ABCA) Is Yet to See Trading Action on Nov 24Thorold News

all 24 news articles »

11/24/2017 04:28 PM


Could EURONEXT NV (OTCMKTS:EUXTF) Go Down After Its ...
WeeklyHub
The stock of EURONEXT NV (OTCMKTS:EUXTF) registered a decrease of 70.14% in short interest. EUXTF's total short interest was 4300 shares in November ...

and more »

11/24/2017 03:16 PM


Fijian Government Selects EUTELSAT 172B for Providing Universal Television Access
Business Wire (press release)
PARIS & SUVA, Fiji--(BUSINESS WIRE)--Walesi, the Fijian Government's Digital Television infrastructure management company, has signed a multi-year agreement with Eutelsat Communications (Euronext Paris: ETL) that will for the first time expand ...

and more »

11/23/2017 09:39 AM


ASSYSTEM :Shareholders approve a capital reduction representing a maximum nominal amount or €6000000
GlobeNewswire (press release)
The AMF and Euronext Paris will publish a notice indicating the conditions under which the public buyback offer will be completed along with the detailed schedule. It is expected that the offer period will run from 24 November 2017 until 14 December ...

and more »

11/22/2017 05:02 PM


Innate Pharma provides an update on Lirilumab
GlobeNewswire (press release)
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today provides an update on the clinical study program of lirilumab, licensed to Bristol-Myers Squibb. Lirilumab is a fully human antibody directed against the inhibitory killer-cell ...

and more »

11/22/2017 04:46 PM